Table 1

Characteristics of identified publications

Publication	Registry source	Indication	All patients	Type of malignancy	NOS quality score^*
Abasolo et al (2008)20^†	BIOBADASER	RA	4529	All	3/2/3
Askling et al (2005)26	ARTIS	RA	4160	Solid	4/2/3
Askling et al (2005)41^†	ARTIS	RA	4160	Haematopoietic (including leukaemia and lymphoma)	4/2/3
Askling (2007)27	ARTIS	RA	6403	All	3/2/3
Askling et al (2009)15^†	ARTIS	RA	6604	All (including haematopoietic and skin)	4/1/3
Askling et al (2009)23^†	ARTIS	RA	6604	Lymphoma	4/2/3
Askling (2009)28^†	ARTIS	RA	6604	Skin	2/1/3
Carmona and Gómez-Reino (2006)42	BIOBADASER	RA and SpA	4536	All	3/0/3
Carmona et al (2007)43	BIOBADASER	RA	789	All	4/2/3
Chakravarty et al (2005)29	NDBRD	RA	15 789	NMSC	2/1/1
Dixon et al (2010)16^†	BSRBR	RA	10 735	All	4/1/1
Du Pan et al (2009)14^†	SCQM-RA	RA	2364	All	2/0/3
Feltelius et al (2005)44	ARTIS	RA	1073	All (including Lymphoma)	3/0/3
Geborek et al (2002)45	SSATG	RA	305	All	3/0/3
Geborek et al (2005)46	SSATG	RA	757	All (including leukaemia and lymphoma)	3/0/2
Gibofsky et al (2009)18^†	RADIUS	RA	2206	All	2/1/2
Greenberg et al (2007)19^†	CORRONA	RA	4651	All (including haematologic and lymphoma and skin)	3/2/3
Hetland et al (2005)47	DANBIO	Rheumatic disease	419	All	3/0/3
Koike et al (2009)48	NR	RA	7091	All	2/0/1
Kristensen et al (2005)49	SSATG	RA	1216	All	2/0/2
Kristensen et al (2008)50	SSATG	PsA	261	Haematopoietic	3/0/3
Mariette et al (2010)25^†	RATIO	Rheumatic disease plus Crohn's disease	NR	Lymphoma	3/2/3
Mercer et al (2009)30^†	BSRBR	RA	11 757	NMSC	3/2/2
Pallavicini et al (2009)24	LOHREN	RA	1064	All (including haematopoietic and lymphoma)	2/2/2
Strangfeld et al (2010)17^†	RABBIT	RA	3346	All	3/2/2
Watson et al (2006)51^†	BSRBR	RA	9999	All	4/2/1
Wolfe and Michaud (2004)21^†	NDBRD	RA	9162	Lymphoma	4/2/2
Wolfe and Michaud (2007)31^†	NDBRD	RA	5257	All and leukaemia and skin	4/2/2
Wolfe and Michaud (2007)22^†	NDBRD	RA	10 834	Lymphoma	4/2/3

↵* Score awarded for the following three areas: selection, score out of 4; comparability, score out of 2; outcome, score out of 3.
↵† To avoid redundancy, these most recent publications reporting data of interest were included in evidence synthesis. Descriptions of the studies and explanations of the acronyms are available in supplementary appendix 3, available online only.
NMSC, non-melanoma skin cancer; NOS, Newcastle–Ottawa scale; NR, not reported; PsA, psoriatic arthritis; RA, rheumatoid arthritis; SpA, spondylarthritis.